2 Cannabis Stocks That Are Quietly Trouncing the Market in 2026

Trulieve Cannabis and Cronos Group have each gained roughly 27% through Sept. 18, outperforming the S&P 500's approximately 12% return. Trulieve reported Q2 revenue of $271 million, 60% gross margin, $98 million of adjusted EBITDA, and $74 million in first-half free cash flow, while Cronos posted record Q2 revenue of $53 million, up 58% year over year, with gross margin rising to 54%. Cronos also held about $827 million in cash and investments and repurchased 12.3 million shares, although both companies remain exposed to cannabis pricing, regulatory and potential Israeli import-restriction risks.

Analysis

CRON’s differentiated setup is balance-sheet optionality rather than simply top-line growth: if international margins hold, its cash-heavy capitalization can fund distribution, brand investment, and buybacks while leveraged Canadian peers face dilution. The market is likely to reward this through multiple expansion only if growth converts to sustained operating cash flow; otherwise, the cash balance becomes a low-return asset and the current rerating stalls. Germany is the highest-value incremental opportunity, but its early-stage market structure also makes reported growth volatile and vulnerable to channel inventory effects.

For Trulieve, the key investable change is a potential reduction in the liquidity and institutional-ownership discount, not a near-term step-change in underlying demand. That discount can compress over 1-3 months if NYSE eligibility, index inclusion prospects, and custody access are independently confirmed. The more important 6-18 month question is whether its cash generation remains durable after normalizing for working-capital movements and deferred tax exposure; a revenue base concentrated in mature U.S. medical markets can produce strong margins but limited organic growth.

The non-consensus risk is that cannabis equities are again pricing regulatory optionality ahead of implementation. Schedule III-related tax relief, exchange access, and banking benefits each require distinct legal, exchange, and operational milestones; any delay would expose high-beta names to sharp multiple compression. For CRON specifically, an adverse Israeli trade ruling would matter disproportionately because international growth is supporting the current narrative; watch for tariff language, import quotas, or customer-order deceleration rather than headline-level investigation updates.

Key Decisions for Investors

• Initiate a small long CRON / short MSOS pair over the next 1-2 weeks: CRON has superior liquidity and a cash buffer, while MSOS retains greater exposure to delayed U.S. regulatory transmission. Target a 15-20% relative return over 3-6 months; exit if CRON’s next quarterly operating cash flow remains materially negative or Israel revenue growth decelerates below 25% year over year.
• Do not chase Trulieve until exchange listing status, free-float expansion, and institutional custody availability are verified. If confirmed, buy on a post-event pullback rather than announcement strength, with a 6-12 month thesis tied to valuation rerating; invalidate on two consecutive quarters of declining revenue without offsetting margin improvement.
• Use Israeli trade-investigation milestones as a CRON risk trigger: reduce exposure ahead of a preliminary duty decision unless management quantifies Israel revenue concentration and mitigation plans. A preliminary tariff or quota would likely overwhelm near-term buyback support and warrants reassessment.
• Monitor CRON’s buyback pace against cash burn and international investment. Accelerated repurchases alongside positive operating cash flow would support a higher-quality capital-return thesis; repurchases funded while operating losses widen should be treated as a valuation support mechanism, not fundamental improvement.